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Background: During pregnancy, women living in malaria-endemic regions are at increased risk of malaria infection
and can harbour chronic placental infections. Intermittent preventive treatment with sulphadoxine-pyrimethamine
(SP-IPTp) is administered to reduce malaria morbidity. It was hypothesized that the presence of placental malaria
infection and SP-IPTp use would increase the risk of peripheral blood gametocytes, the parasite stage that is
transmissible to mosquitoes. This would suggest that pregnant women may be important reservoirs of malaria
transmission.
Methods: Light microscopy was used to assess peripheral gametocytaemia in pregnant women enrolled in a
longitudinal, observational study in Blantyre, Malawi to determine the association between placental malaria and
maternal gametocytaemia. The relationship between SP-IPTp and gametocytaemia was also examined.
Results: 2,719 samples from 448 women were analysed and 32 episodes of microscopic gametocytaemia were
detected in 27 women. At the time of enrolment 22 of 446 women (4.9%) had gametocytaemia and of the 341
women for whom there was sufficient sampling to analyse infection over the entire course of pregnancy, 27 (7.9%)
were gametocytaemic at least once. Gametocytaemia at enrolment was associated with placental malaria, defined
as malaria pigment or parasites detected by histology or qPCR, respectively (OR: 32.4, 95% CI: 4.2-250.2), but was
not associated with adverse maternal or foetal outcomes. Administration of SP-IPTp did not affect gametocyte
clearance or release into peripheral blood.
Conclusions: Gametocytaemia is present in 5% of pregnant women at their first antenatal visit and associated with
placental malaria. SP-IPTp does not alter the risk of gametocytaemia. These data suggest that pregnant women are
a significant reservoir of gametocyte transmission and should not be overlooked in elimination efforts. Interventions
targeting this population would benefit from reaching women prior to first antenatal visit.
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Malaria is a major cause of morbidity and mortality world-
wide and it disproportionately affects children and preg-
nant women. Every year, 125 million pregnancies occur in
malaria-endemic countries [1]. Pregnancy-associated mal-
aria can result in maternal anaemia, low birth weight, pre-
maturity, and increased infant mortality [2-8]. Women
become vulnerable to malaria during their first and sec-
ond pregnancies because they lack adequate immunity to* Correspondence: sarah.boudova@som.umaryland.edu
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unless otherwise stated.variant surface proteins expressed by the parasite on the
surface of infected red blood cells, allowing the infected
cells to sequester in the placenta, a protected environment
where the parasite can remain throughout pregnancy
[9-12]. While asexual blood stage malaria infection causes
malaria disease and is the focus of surveillance and pre-
vention studies that have targeted pregnant women,
sexual stage gametocyte infection is responsible for mal-
aria transmission to the mosquito. Pregnant women
have largely been overlooked as a potential reservoir for
gametocytes despite their increased susceptibility to
malaria, and prolonged infections due to placental se-
questration. As interest in malaria elimination increases,al. This is an Open Access article distributed under the terms of the Creative
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iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Boudová et al. Malaria Journal 2014, 13:506 Page 2 of 8
http://www.malariajournal.com/content/13/1/506the extent to which pregnant women with placental
malaria contribute to the burden of malaria transmis-
sion requires investigation.
In addition to placental sequestration increasing the risk
of malaria infection and gametocytaemia, anti-malarial
interventions may impact the transmission potential of
pregnant women. The current strategy to protect against
the adverse effects of placental malaria is intermittent
preventive treatment in pregnancy with sulphadoxine-
pyrimethamine (SP-IPTp) given two to three times dur-
ing pregnancy [13]. However, evidence suggests that SP
can cause release of sequestered gametocytes into the
peripheral blood that may persist at low levels for over a
month [14-17]. Thus, the use of SP-IPTp may also in-
crease the likelihood that pregnant women will have
gametocytaemia.
To test the hypothesis that pregnant women serve as
reservoirs of malaria transmission in malaria-endemic set-
tings, the prevalence of gametocytaemia during pregnancy
was measured in an observational study. The observa-
tional study reflected the natural history of gametocytae-
mia in pregnant women in a malaria-endemic area who
received standard dosing of SP-IPTp. The association be-
tween placental infection or SP-IPTp and the presence of
gametocytes was assessed.
Methods
Study site and population
Pregnant women were offered enrolment in an observa-
tional study of pregnant women conducted in Ndirande,
a peri-urban township of Blantyre, Malawi. Malaria trans-
mission occurs year-round with a seasonal peak during
the three- to four-month rainy season. Women were en-
rolled at their first antenatal visit if they were in their first
or second pregnancy and at less than or equal to 28 weeks
of gestation. Women were excluded if they had any major
illness requiring high-risk obstetric care, HIV infection or
chronic antibiotic treatment. Women were followed
through delivery. Details of the study design and primary
study results have been published previously [18]. Gesta-
tional age at enrolment was calculated based on the last
menstrual period or by fundal height if the last menstrual
period was not known. Gestational age at delivery was es-
timated based on the last menstrual period and the Ballard
score; the fundal height at enrolment was included in the
estimate if the last menstrual period and Ballard estimates
were more than two weeks discrepant.
Study procedures
Women attended routine clinic visits every four weeks
and were encouraged to return any time they were ill. At
all visits, including routine visits and whenever there was
an illness with symptoms suggestive of malaria, history
and physical examination were performed, with axillarytemperature recorded and a fever defined as ≥37.5°C.
Thick and thin malaria smears were collected and drops
of blood were collected on filter paper. Malaria smears
were field-stained and examined using light microscopy
with a 100× oil immersion lens. Parasitaemia was assessed
by counting the number of parasites per 200 leukocytes
and examining 100 high-power fields before considering a
smear to be malaria-negative. All slides were read by two
microscopists and in cases of disagreement between the
readings, the conflict was adjudicated by a third expert
reader. Parasite density was calculated based on 8,000 leu-
kocytes per microlitre. All smears identified as having
parasitaemia in the observational study were classified as
having asexual-stage infection and were treated with
artemether-lumefantrine.
Participants were given SP-IPTp up to three times in
pregnancy during prenatal follow-up, in accordance with
national policy in Malawi. At delivery the placenta was col-
lected for molecular and histopathological examination.
Newborns were assessed and gestational age was estimated
as previously described [19]. Haemoglobin measurements
were obtained from a finger-prick blood sample using
HemoCue® AB. Ethical approval was obtained from the
University of Malawi College of Medicine’s Research Ethics
Committee and the University of Maryland Baltimore
Institutional Review Board. Written informed consent was
obtained from all participants before conducting any
study-related activities. Participants had the option to with-
draw from the study at any time. All data were recorded
and analysed anonymously.
Identification of gametocytes
After completion of the observational study, dried blood
spots collected on filter paper from all antenatal visits
were subjected to quantitative real-time PCR (qPCR) for
Plasmodium falciparum lactate dehydrogenase to detect
infection. Extraction and PCR protocols are described
online [20]. A peripheral blood specimen was considered
uninfected if the qPCR was negative. For all qPCR-positive
filter papers, the corresponding blood smear was examined
for gametocytes; in cases where no filter paper specimens
were available, the blood smear was examined for gameto-
cytes. Smears re-examined for gametocytes were counted
per 1,000 leukocytes. Gametocyte density was calculated
based on 8,000 leukocytes per microlitre. The entire
smear was scanned before being considered negative for
gametocytes. All slides were read for gametocytes by
one microscopist.
Identification of placental malaria
Placental tissue biopsies were processed as previously
described [18] and examined for the presence of malaria
haemozoin and parasites. Placental blood filter papers
were subjected to qPCR as described above. Placental
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ology or placental parasites by qPCR. If the histology and
the qPCR were negative, the placenta was considered
uninfected.
Data analysis
Dried blood spots and corresponding blood smears were
examined from all women at enrolment prior to the ad-
ministration of SP-IPTp. To determine the prevalence of
gametocytaemia during pregnancy, data were included
from all women who had gametocytaemia at any time
during pregnancy. Women were classified as not having
gametocytaemia during pregnancy if they had specimens
available for analysis from enrolment and at least two
months of follow-up. Data from one placenta of twin ges-
tations were included in analyses of placental malaria but
excluded from analyses of birth outcomes. When placen-
tal results were discordant, only the positive placental re-
sult was included.
To determine the effect of SP on gametocyte clear-
ance, all women who were considered malaria-negative
in the observational study (and therefore not treated
with artemether-lumefantrine) but subsequently found
to be gametocyte-positive at enrolment were included. To
examine the effect of SP on gametocyte release, women
who were gametocyte-negative by microscopy but had
sub-microscopic infection (malaria-positive by qPCR, but
negative by microscopy in the observational study and
gametocyte analysis) at the time of enrolment were evalu-
ated. In both analyses, the proportion of women with
gametocytaemia at their visit one month after enrolment
was compared using Fisher’s exact test.
Data analysis was performed using STATA version 12.0
software (Stata Corp, College Station, TX, USA). Descrip-
tive statistics were analysed using frequencies and percent-
ages for categorical data and geometric means, means,
medians, and 95% confidence intervals for continuous var-
iables. 95% confidence intervals were calculated for all
proportions and prevalence rates. To measure prenatal
risk factors and outcomes associated with gametocytae-
mia, logistic regression was used to calculate odds ratios.
For the multivariate model, any parameter in the univari-
ate model associated with gametocytaemia with p ≤ 0.1
was considered. Maternal treatment for malaria prior to
enrolment, asexual stage parasitaemia at enrolment, mean
maternal haemoglobin at enrolment, haemozoin in the
placenta, and parasites detected in the placenta by qPCR
were included. All p-values are two-sided and statistical
significance was set at p ≤ 0.05.
Results
Prevalence of gametocytaemia and placental malaria
A total of 2,719 blood smears from 448 women were
available and read for gametocytes if the correspondingfilter-paper blood spot was qPCR-positive for malaria.
Thirty-two episodes of gametocytaemia in 27 women were
detected. Twenty-two (68.7%) of the gametocyte episodes
occurred at the enrolment visit and all episodes of game-
tocytaemia occurred within two months of enrolment.
Five women had gametocytaemia twice during their par-
ticipation in the study. The geometric mean gametocyte
density among gametocyte-positive smears was 19.9 ga-
metocytes per microlitre of blood (95% CI: 13.3-29.8).
At enrolment, 22 of 446 (4.9%) smears were positive
for gametocytes. Enrolment smears from two women
were damaged and could not be evaluated. The gametocyte
prevalence was approximately ten-fold higher among those
women with asexual-stage malaria detected by light mi-
croscopy compared to those without infection detected by
light microscopy (12/60, 20.0% vs 10/386, 2.6%). Among
the 341 participants who had sufficient data to evaluate the
presence of any gametocytes during pregnancy, 27 (7.9%)
had at least one episode of gametocytaemia. The propor-
tion of women with gametocytaemia during pregnancy was
higher among women who had asexual-stage malaria de-
tected by light microscopy at least once during pregnancy,
18 of 65 (27.7%), as compared to nine of 276 (3.3%, p <
0.01) for those without asexual-stage infection detectable
by microscopy.
Molecular data was available from 321 placentas and
histology was available for 311. One-hundred and ten
(34.3%) women had evidence of placental malaria either
by histology, qPCR or both. Among the 311 women with
both histology and qPCR data available, 33 (10.6%) had
placental parasites alone, 38 (12.2%) had haemozoin
alone, 33 (10.6%) had both parasites and haemozoin, and
207 women had neither. Of the ten placentas for which
histology was unavailable, six (60%) had placental mal-
aria by qPCR.
Risk factors associated with gametocytaemia at enrolment
At enrolment, gametocytaemia was associated with pla-
cental malaria, lower maternal haemoglobin and the pres-
ence of asexual stage infection. Age, gravidity, gestational
age, history of malaria treatment, maternal temperature at
enrolment and bed net use were not associated with gam-
etocyte infection (Table 1). No women with malaria infec-
tion had complaints of febrile illness at their enrolment
visit and only 7 of 102 (6.9%) women with malaria infec-
tion had a fever at the time of their evaluation. No women
with gametocytaemia had a measured fever. Placental mal-
aria, with evidence of haemozoin and/or qPCR, was asso-
ciated with 30-fold increased odds of gametocytaemia at
enrolment (Table 1). In univariate analysis both haemo-
zoin and qPCR detection of placental malaria were associ-
ated with gametocytaemia at enrolment. In multivariate
analysis, haemozoin was associated with gametocytaemia
at enrolment (OR: 10.3, 95% CI: 1.9-55.1). Molecular
Table 1 The relationship between gametocytaemia at enrolment and placental malaria
Univariate analysis Multivariate
Gametocytes No gametocytes OR 95% CI P value OR 95% CI P value
Placental malaria (haemozoin or qPCR) 14/15 (93.3%) 89/295 (30.2%) 32.4 4.2 - 250.2 <0.01 -- -- --
Haemozoin 12/15 (80.0%) 58/295 (19.7%) 16.3 4.5-59.8 <0.01 10.3 1.9 – 55.1 <0.01
qPCR 9/15 (60.0%) 62/304 (20.4%) 5.9 2.0-17.1 <0.01 2.8 0.8 – 9.3 0.09
Mean maternal haemoglobin (g/dL) at enrolment
(standard deviation)
10.9 (1.5) 11.8 (1.6) 0.7 0.6 – 1.0 0.02 1.1 0.7 – 1.5 0.76
Asexual stage parasitaemia at enrolment 12/22 (54.5%) 48/424 (11.3%) 9.4 3.9 – 22.9 <0.01 1.4 0.4 – 5.8 0.62
Malaria treatment prior to enrolment 6/22 (27.3%) 56/422 (13.2%) 2.5 0.9 – 6.5 0.09 2.8 0.8 – 10.1 0.11
Mean maternal age in years (standard deviation) 20.3 (3.1) 20.1 (3.2) 1.0 0.9 – 1.2 0.77 -- -- --
Primigravid 13/22 (59.1%) 268/424 (63.2%) 1.2 0.5 – 2.8 0.70 -- -- --
Mean gestational age in weeks at the time of enrolment
(standard deviation)
20.1 (4.0) 20.1 (4.4) 1.0 0.9 – 1.1 0.97 -- -- --
Mother slept under a bed net the previous night 9/22 (40.9%) 211/422 (50.0%) 1.4 0.6 – 3.5 0.40 -- -- --
Maternal axillary temperature (°C) at enrolment
(standard deviation)
36.5 (0.4) 36.6 (0.4) 0.8 0.3 – 2.2 0.72 -- -- --
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bin at enrolment, and asexual stage infection at enrolment
were not associated with gametocytaemia at enrolment.
Gametocytaemia and maternal and foetal outcomes
Gametocytaemia at enrolment or at any time during
pregnancy was not associated with differences in gesta-
tional age at birth, birth weight or maternal haemoglobin
concentration at delivery.
The effect of SP on gametocytaemia
When examining women who had gametocytaemia at en-
rolment, all women cleared gametocytes within one month
regardless of whether they received SP (Figure 1A). Among
women with sub-microscopic infection, the rates of game-
tocytaemia one month later were low and were not differ-
ent between women who did or did not receive SP-IPTp
(0% vs 6.1%, p = 0.5, Figure 1B).
Discussion
These data show 5% gametocyte prevalence at the time
of first antenatal visit and increased odds of peripheral
gametocytaemia among women with evidence of placen-
tal malaria at delivery. This association was independent
of asexual stage parasitaemia. When examined separately
in a multivariate model, the presence of haemozoin, was
associated with gametocytaemia at the time of enrolment
and the association with active placental malaria infection
did not achieve statistical significance (p = 0.09). In the
context of SP-IPTp and active case detection and treat-
ment with artemether-lumefantrine, episodes of gametocy-
taemia were rare after initiating antenatal care. All episodes
of gametocytaemia occurred within two months of enrol-
ment. No association between SP and either gametocyterelease into peripheral blood or gametocyte clearance
was found.
This is the first study examining the relationship be-
tween placental malaria and gametocytaemia, and one of
the few studies examining gametocytaemia in the context
of pregnancy. A previous study in Tanzania documented a
high prevalence of gametocytaemia (12-23%) in pregnant
women with microscopically confirmed malaria [21]. This
is comparable to the 20% gametocyte prevalence observed
among women with asexual-smear-positive malaria at en-
rolment in this study. However, the Tanzanian study did
not capture the full burden of gametocytaemia during
pregnancy because only symptomatic women were in-
cluded and most malaria infections during pregnancy are
asymptomatic.
The prevalence of gametocytaemia among pregnant
women in this study is similar to that of children in the
region, suggesting that pregnant women serve as a po-
tentially important reservoir of malaria transmission, just
as malaria-naïve children do. The prevalence of gameto-
cytes among children with symptomatic uncomplicated
malaria was 22.6% in Tanzania [15], which is similar to
the 20% found in this study. Gametocyte prevalence in
the entire pregnant population at enrolment in this study
was 4.9% consistent with the prevalence of 5.6% seen in a
cross-sectional study of children in Mozambique [22].
A direct comparison cannot be made between preg-
nant and non-pregnant adults due to a lack of data on
non-pregnant adult gametocyte prevalence in Malawi
and neighbouring countries. However, it has been ob-
served in multiple African settings, that with increasing
age, gametocyte prevalence drops rapidly [23,24].
Although the rates of gametocytaemia are similar be-
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Figure 1 The relationship between SP-IPTp and gametocytaemia. A. Clearance of gametocyte infection within one month following
treatment with SP vs no treatment. B. Release of gametocytes within one month after SP vs no treatment.
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infections are almost always asymptomatic—as was the
case for all women in this study at the time of enrolment—
whereas children are more likely to exhibit symptoms of
malaria leading to treatment intervention, potentially redu-
cing their transmission potential. Although young children
contribute a larger proportion of the transmission reservoir
than pregnant women [25], the identification of pregnant
women as an important source of transmission would re-
quire interventions that are different from young children.
There are several limitations to this characterization of
gametocyte prevalence. All of the women enrolled were
in their first or second pregnancy, and therefore at
higher risk of pregnancy-associated malaria and placen-
tal malaria than multigravid women. Thus the gameto-
cyte prevalence in the general pregnant population may
be overestimated. However, because this study was limited
to detecting gametocytes by light microscopy, the results
likely underestimate the true prevalence of gametocytes.
Light microscopy is insufficiently sensitive to detect all in-
fections that are transmissible to mosquitoes. Comparing
molecular methods with microscopy, Bousema et al. [15]
observed over a three-fold increase in gametocyte preva-
lence. These sub-microscopic concentrations of gameto-
cytes can be infectious to mosquitoes in a blood meal [26].
In addition, the circumstances of this clinical study likely
led to an overall decrease in the observed prevalence of
gametocytaemia. Women in the study were followed by ac-
tive case detection and treated for all episodes of malaria
infection with artemether-lumefantrine, even in the ab-
sence of symptoms. Women were only enrolled at their
first antenatal visit, usually well into their second trimester,thus it is probable that cases of gametocytaemia were
missed in the early pregnancy period.
The high rate of gametocytaemia and its association
with placental malaria infection suggests that pregnancy,
and possibly the presence of placental sequestration put
pregnant women at risk for gametocytaemia. Gameto-
cytes are very rarely found in the placenta [27], making
sequestration of gametocytes themselves in the placenta
an unlikely explanation for the association between placen-
tal malaria and peripheral gametocytaemia in pregnancy.
While the observed association may reflect higher malaria
exposure in women with gametocyte infection, there are
several possible physiological explanations for this novel
finding. First, gametocytes may express, pregnancy-specific
surface proteins against which women lack immunity. This
seems possible since asexual stages are known to express a
novel surface protein, VAR2CSA during pregnancy, against
which primi- and secondi-gravid women lack immunity
[11,12]. Another possibility is that adult women have
weak gametocyte-specific immunity. Adults living in
malaria-endemic regions develop protective immunity
against asexual-stage parasites with repeated exposure.
Efficient immune clearance of parasites may prevent
parasites from surviving long enough to develop into
gametocytes. In support of this theory, it has been dem-
onstrated that gametocyte-specific immunity is inversely
correlated with age [28]. However during pregnancy,
asexual stage parasites evade immune clearance via placen-
tal sequestration and thus have the potential to develop
into gametocytes. Since adults have weak gametocyte-
specific immunity, the sexual stage of the parasite may per-
sist resulting in an increased prevalence of gametocytaemia
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the bone marrow, the site of gametocyte enrichment and
development [29], could alter gametocyte prevalence. Preg-
nancy causes bone marrow hyperplasia and reticulocytosis
[30]. Structural changes to the bone marrow could reduce
the extravascular space in the bone marrow forcing ga-
metocytes into the periphery. Alternatively, bone mar-
row hyperplasia could result in an expansion of the
environment where gametocytes develop and a subse-
quent increase in gametocyte production. Although the
mechanism is unknown, reticulocytes have been shown
in vitro to increase gametocytogenesis [31]. The increase
in reticulocyte levels in pregnancy could drive gametocyte
production and thus gametocyte prevalence. The mechan-
ism by which pregnancy promotes gametocytaemia merits
further examination.
In this limited sample size, no association between SP
prophylaxis and gametocytaemia was detected. This is con-
sistent with a previous study demonstrating that SP-IPT in
children decreased gametocytaemia [32]. The increase in
gametocytaemia typically occurs one week after SP admin-
istration [14,16,17], so the one-month sampling time frame
may have missed a transient rise in gametocytes. However,
the overall findings indicate that microscopically detectable
gametocytaemia disappeared by three months of study in-
terventions, which included repeated dosing of SP-IPTp,
providing support for the conclusion that SP-IPTp does
not promote gametocyte production or release.
Most cases of gametocytaemia in this study occurred
at the time of enrolment, suggesting that pregnant women
may be an important source of malaria transmission early
in pregnancy. This has significant public health implica-
tions. It highlights the need for interventions aimed at
preventing malaria to reach women earlier in pregnancy.
This study and others [18,19] have clearly demonstrated
the need to reach pregnant women early in their preg-
nancy, before malaria infection occurs. This is particularly
concerning since it is typical for women in sub-Saharan
Africa to wait until half-way through pregnancy before
seeking antenatal care [33,34] potentially allowing gameto-
cytaemia to persist for months. The results of this study
highlight the urgent need to promote antenatal attendance
early in pregnancy. In addition to expanding opportunities
to clear gametocytaemia, other benefits include earlier ac-
cess to sexually transmitted disease testing, iron-folate
supplements and insecticide-treated nets. If cultural sensi-
tivity about revealing pregnancy status early in gestation
cannot be overcome [35], this study and others justify
the exploration of interventions that target all women of
child-bearing potential [18,19]. There is an urgent need
for alternatives to SP that can be used early in preg-
nancy, are not compromised by resistance and are dif-
ferent enough from current first-line therapy to avoid
selection for resistant parasites. In Malawi and otherareas of Africa, the return of chloroquine-susceptible mal-
aria after cessation of chloroquine use raises the possibility
that chloroquine alone or in combination may serve this
purpose. Studies are currently underway to evaluate this
option.
It is also possible that maternal gametocytaemia could
impact foetal and infant immunity. Gametocytaemia could
result in increased production of gametocyte-specific anti-
bodies that would be transferred to the infant providing
protection against gametocyte carriage in infancy. Like
asexual-stage proteins [36], gametocyte proteins could
traverse the placenta in immune complexes causing foetal
immune priming with the potential to predispose the in-
fant to either elevated effector responses to gametocytes
or immune tolerance to this life stage.
The results of this study raise the possibility that activity
against gametocytes may be important in the selection of
strategies to prevent and control pregnancy-associated mal-
aria. Although all cases of gametocytaemia were cleared
within three months of participation in the study, study in-
terventions were extensive, including SP-IPTp, which is not
gametocidal, and treatment with artemether-lumefantrine,
which is known to have some activity against gametocytes.
This study was not able to evaluate the relationship be-
tween artemether-lumefantrine treatment and gametocy-
taemia. It is possible that clearance of asexual stages via
IPTp is sufficient to prevent gametocyte development from
the asexual stages, and thus prevent gametocytaemia. Alter-
natively, the treatment targeting asexual stages may allow
gametocytes to remain in the periphery and bone marrow,
or may even promote gametocytogenesis. IPTp with drugs
with known gametocidal activity, such as the artemisinin
derivatives may be necessary to prevent parasite transmis-
sion. Further study is needed to elucidate the mechanism of
gametocytogenesis and determine which drugs are the most
effective in clearing infections and also preventing trans-
mission. The results of this study highlight the critical role
of preventing malaria in pregnant women, not only to pro-
tect the health of the mother and the infant but also to
make progress towards malaria elimination.
Conclusion
Gametocytaemia was observed in 5% of pregnant women
before they initiated antenatal care and began receiving
IPTp. Placental malaria is associated with increased odds
of gametocytaemia in pregnancy independently of asexual
stage parasitaemia. In this study, there is no evidence that
SP-IPTp increases the presence of gametocytes. Overall
these data suggest that pregnant women may be a signifi-
cant reservoir of gametocytes and should not be over-
looked in malaria elimination strategies.
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